在痛风患者中实现血清尿酸目标：一项针对痛风专科风湿病诊疗实践的审计
Achieving serum urate targets in gout: an audit in a gout-oriented rheumatology practice.
作者信息
Corbett Elizabeth J M, Pentony Peta, McGill Neil W
机构信息
Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Department of Rheumatology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
出版信息
Int J Rheum Dis. 2017 Jul;20(7):894-897. doi: 10.1111/1756-185X.13032. Epub 2017 Feb 16.
AIM
To assess the proportion of patients with gout who achieve target serum urate levels, the drug regime required and the reasons for failing to do so.
METHODS
We reviewed the files of all patients with gout who presented to a gout-oriented rheumatology practice between January 2010 and September 2014.
RESULTS
Two hundred and thirty patients agreed to commence urate lowering therapy (ULT); 73% achieved their urate target, including 74% with non-tophaceous gout (target ≤ 0.36 mmol/L) and 71% with tophi (target ≤ 0.30 mmol/L). Of the 62 who failed to reach target, in 61 it was due to non-adherence and in one due to inefficacy.
CONCLUSION
Adherence remains the major challenge to successful long-term gout management.
目的
评估痛风患者达到血清尿酸目标水平的比例、所需药物治疗方案以及未达标的原因。
方法
我们回顾了2010年1月至2014年9月期间到以痛风为主的风湿病诊所就诊的所有痛风患者的病历。
结果
230例患者同意开始降尿酸治疗（ULT）；73%的患者达到尿酸目标，其中非痛风石性痛风患者（目标值≤0.36 mmol/L）达标率为74%，痛风石患者（目标值≤0.30 mmol/L）达标率为71%。在未达标的62例患者中，61例是由于未坚持治疗，1例是由于治疗无效。
结论
坚持治疗仍然是痛风长期成功管理的主要挑战。
Zotero 插件